Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

Cerilliant
Deloitte
Merck
Dow
UBS
Chinese Patent Office
Harvard Business School
Mallinckrodt
US Army

Generated: August 17, 2018

DrugPatentWatch Database Preview

Glaxosmithkline Con Company Profile

« Back to Dashboard

Summary for Glaxosmithkline Con
International Patents:315
US Patents:11
Tradenames:12
Ingredients:11
NDAs:16

Drugs and US Patents for Glaxosmithkline Con

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Glaxosmithkline Cons LAMISIL terbinafine hydrochloride SOLUTION;TOPICAL 020749-001 Oct 17, 1997 DISCN No No ➤ Try a Free Trial ➤ Try a Free Trial
Glaxosmithkline Cons FLONASE SENSIMIST ALLERGY RELIEF fluticasone furoate SPRAY, METERED;NASAL 022051-002 Aug 2, 2016 OTC Yes Yes 9,320,862 ➤ Try a Free Trial Y ➤ Try a Free Trial
Glaxosmithkline Cons VOLTAREN diclofenac sodium GEL;TOPICAL 022122-001 Oct 17, 2007 AB RX Yes Yes ➤ Try a Free Trial ➤ Try a Free Trial
Glaxosmithkline Cons TAVIST-1 clemastine fumarate TABLET;ORAL 020925-001 Aug 21, 1992 OTC Yes Yes ➤ Try a Free Trial ➤ Try a Free Trial
Glaxosmithkline Cons LAMISIL AT terbinafine hydrochloride SPRAY;TOPICAL 021124-002 Mar 17, 2000 OTC Yes Yes ➤ Try a Free Trial ➤ Try a Free Trial
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial

Expired US Patents for Glaxosmithkline Con

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Glaxosmithkline Cons EXCEDRIN (MIGRAINE) acetaminophen; aspirin; caffeine TABLET;ORAL 020802-001 Jan 14, 1998 5,972,916 ➤ Try a Free Trial
Glaxosmithkline Cons LAMISIL terbinafine GEL;TOPICAL 020846-001 Apr 29, 1998 4,680,291 ➤ Try a Free Trial
Glaxosmithkline Cons LAMISIL AT terbinafine hydrochloride SPRAY;TOPICAL 021124-002 Mar 17, 2000 5,681,849*PED ➤ Try a Free Trial
Glaxosmithkline Cons LAMISIL AT terbinafine hydrochloride SOLUTION;TOPICAL 021124-001 Mar 17, 2000 5,681,849*PED ➤ Try a Free Trial
Glaxosmithkline Cons NICORETTE nicotine polacrilex TROCHE/LOZENGE;ORAL 021330-001 Oct 31, 2002 5,110,605 ➤ Try a Free Trial
Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial

Paragraph IV (Patent) Challenges for GLAXOSMITHKLINE CON drugs
Drugname Dosage Strength Tradename Submissiondate
➤ Subscribe Capsules 60 mg ➤ Subscribe 2010-09-08
➤ Subscribe Gum 4 mg ➤ Subscribe 2013-01-22
➤ Subscribe Gum 2 mg ➤ Subscribe 2013-01-22

Non-Orange Book US Patents for Glaxosmithkline Con

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
6,787,532 Formulation containing anti-inflammatory androstane derivatives ➤ Try a Free Trial
7,629,335 Anti-inflammatory androstane derivative ➤ Try a Free Trial
6,537,983 Anti-inflammatory androstane derivatives ➤ Try a Free Trial
7,592,329 Crystalline complexes of fluticasone-2-furoate ➤ Try a Free Trial
7,798,368 Fluid dispensing device ➤ Try a Free Trial
Patent No. Title Estimated Patent Expiration

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial

Supplementary Protection Certificates for Glaxosmithkline Con Drugs

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
C0014 France ➤ Try a Free Trial PRODUCT NAME: FLUTICASONE FLUORATE; REG. NO/DATE: EU/1/07/434/001 20080111
2008 00022 Denmark ➤ Try a Free Trial
C/GB98/044 United Kingdom ➤ Try a Free Trial PRODUCT NAME: ORLISTAT; REGISTERED: UK EU/1/98/071/001 19980729; UK EU/1/98/071/002 19980729; UK EU/1/98/071/003 19980729; UK EO/1/98/071/004 19980729; UK EU/1/98/071/005 19980729; UK EU/1/98/071/006 19980729
C0021 Belgium ➤ Try a Free Trial PRODUCT NAME: LANSOPRAZOLE; NAT. REG.: 150 S 539 F 4 19921119; FIRST REG.: FR 333 412.1 19901211
12/2008 Austria ➤ Try a Free Trial PRODUCT NAME: FLUTICASON FUROAT UND DESSEN SOLVATE
Supplementary Protection Certificate SPC Country SPC Expiration SPC Description

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial

Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Daiichi Sankyo
Medtronic
Cantor Fitzgerald
Cipla
McKesson
UBS
Argus Health
Cerilliant
Farmers Insurance

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.